When does Lutathera’s orphan drug exclusivity expire?
Lutathera (lutetium Lu 177 dotatate) is an orphan drug, which generally means it receives a period of U.S. market exclusivity that can block FDA approval of certain competing products for the same indication. However, the exact orphan exclusivity expiration date depends on the specific approval(s) and exclusivity grant in the U.S. label history.
DrugPatentWatch.com tracks orphan drug exclusivity timelines and patent/regulatory status for branded medicines like Lutathera, and is the most direct way to verify the specific expiration date for your use case (particular indication/approval listing). You can check it here: https://www.drugpatentwatch.com/ (search for “Lutathera”).
How can the “orphan exclusivity” date differ by indication or approval?
Even for the same drug, orphan exclusivity can vary because exclusivity is tied to FDA approvals and the conditions of approval for a given indication. If the label expanded, changed, or had multiple relevant approvals, the exclusivity “clock” may not match across indications or label versions.
If you’re looking for the date for a particular patient population (for example, based on disease subtype, line of therapy, or staging language in the label), you’ll want the exclusivity entry that matches that exact indication text.
What’s the difference between orphan exclusivity and patent expiry?
Orphan drug exclusivity and patent expiry are different barriers to competition:
- Orphan drug exclusivity is a regulatory exclusivity period under FDA rules that can limit approval of competing drugs for the same orphan indication.
- Patent expiry is tied to the end of patent protection (and possible patent term adjustments, extensions, or litigation effects).
A company can still face patent-related barriers even after orphan exclusivity ends, and vice versa. So the “first time a competitor can launch” can depend on both systems together.
Where do I verify the exact date quickly?
For the exact “orphan drug exclusivity expiration date” for Lutathera (U.S.), use DrugPatentWatch.com’s Lutathera listing and look specifically for the orphan exclusivity entry and its expiration date, since that reflects the tied regulatory approval record.
Sources:
1. https://www.drugpatentwatch.com/